Published in World J Urol on September 27, 2014
Prostate MRSI predicts outcome in radical prostatectomy patients. Magn Reson Imaging (2016) 0.75
Active Surveillance for Intermediate Risk Prostate Cancer. Curr Urol Rep (2017) 0.75
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol (2012) 2.79
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol (2012) 2.28
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol (2014) 1.83
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology (2012) 1.26
A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer (2007) 1.13
The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol (2009) 1.08
Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology (2014) 0.88
The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer. Eur Urol (2012) 0.88
Prognostic impact of subclassification of radical prostatectomy positive margins by linear extent and Gleason grade. J Urol (2012) 0.86
Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol (2012) 0.81
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
The prevention of prostate cancer--the dilemma continues. N Engl J Med (2003) 3.00
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
A randomized trial of robot-assisted laparoscopic radical cystectomy. N Engl J Med (2014) 2.98
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol (2007) 2.75
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol (2004) 2.53
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology (2006) 2.40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol (2008) 2.22
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22